Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
Phase 2 Recruiting
50 enrolled
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Phase 1 Recruiting
127 enrolled
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 Recruiting
21 enrolled
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Phase 1 Recruiting
10 enrolled
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Phase 2 Recruiting
58 enrolled
FLASH2
Phase 3 Recruiting
80 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Phase 1 Recruiting
60 enrolled
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Phase 1 Recruiting
20 enrolled
Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
Recruiting
100 enrolled
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Phase 2 Recruiting
30 enrolled
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting
200 enrolled
FIL_CTCL
Recruiting
400 enrolled
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 Recruiting
48 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting
2,000 enrolled
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Phase 2 Recruiting
34 enrolled
Photopheresis in Early-stage Mycosis Fungoides
Phase 2 Recruiting
74 enrolled
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
46 enrolled
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Recruiting
15 enrolled
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Recruiting
100 enrolled
SKINERGY
Recruiting
840 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Phase 2 Recruiting
30 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
A Registry for People With T-cell Lymphoma
Recruiting
1,000 enrolled
Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
Recruiting
100 enrolled
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Recruiting
60 enrolled
BIO-MUSE
Recruiting
120 enrolled
AMITY
Recruiting
100 enrolled
GR-CTCL_CL
Recruiting
40 enrolled